InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.40
(
0.69%
)
Bitcoin
63,795.47
(
0.27%
)
Post# of 4273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Opti Mist

Send PM Follow Ignore
Followers 52
Posts 4109
Boards Moderated 0
Alias Born 07/03/2005

Opti Mist

Re: None

Tuesday, 08/14/2018 5:10:20 PM

Tuesday, August 14, 2018 5:10:20 PM

Post# of 4273
Synergy Pharma: Sales Ramp Ignored
Aug. 14, 2018 2:55 PM ET|13 comments | About: Synergy Pharmaceuticals, Inc. (SGYP), Includes: ESRX


Stone Fox Capital

Summary

Synergy Pharma continues a slow ramp of Turlance prescriptions.
Significant cost controls helped cut the quarterly loss my nearly $10 million.

The Express Scripts deal for 2019 places the biotech on a path to a huge sales ramp by Q2'19.

Synergy Pharma (SGYP) has made several rallies towards $2, but the biotech stock hasn't held any gains despite improving prescription numbers for Trulance that treats IBS. The business developments during the last few months sets the stock up for a sustainable rally.

https://seekingalpha.com/article/4199100-synergy-pharma-sales-ramp-ignored

Opti

Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up